Published : 02 Jul 2026
CHICAGO, IL — July 2, 2026 — Aagami, Inc., a premier global life sciences consulting firm, today announced it has been appointed by an innovative clinical-stage cardiovascular company to secure strategic business arrangements for its flagship therapeutic asset, a novel Fixed-Dose Combination (FDC) antiarrhythmic drug.
Under the new mandate, Aagami will assist the company in exploring global commercial opportunities, including out-licensing, co-development partnerships, and strategic Series A funding to advance the asset through its upcoming clinical milestones.
The asset is a patent-protected, Phase 3-ready Fixed-Dose Combination (FDC) designed for the prevention and treatment of Atrial Fibrillation (AF). The FDC combines two highly effective, ion-channel rhythm control medications (dofetilide and mexiletine) with a unique safety profile designed to preserve therapeutic efficacy while suppressing drug-induced QT prolongation and cardiac risks.
Key advantages of the asset include:
Elimination of In-Patient Onboarding: By mitigating cardiac safety risks, this novel combination holds the potential to completely eliminate the standard 3-day hospital stay currently required for traditional onboarding procedures.
Regulatory Readiness: The asset is Phase 3-ready, with the US FDA having already successfully reviewed the clinical protocol design.
Unmet Medical Need: With no new rhythm-control medication approvals in the AF space in nearly 20 years, this asset addresses a massive clinical gap for both mild and chronic patients who face limitations with current drug toxicities or surgical ablation.
Atrial Fibrillation affects over 33 million people worldwide, and the total addressable market is estimated at over $2.7 Billion. Financial and clinical models project that this unique asset has the potential to serve over 700,000 patients, with peak annual sales forecasted to exceed $1 Billion.
Aagami’s mandate will focus on two core parallel tracks:
Strategic Licensing & Commercial Partnerships: Identifying global pharmaceutical partners focused on the cardiovascular space to lead commercialization. Because the foundational rhythm control mechanism is not heavily marketed in Europe or Asia, major regional licensing opportunities are open for international market entry.
Series A Funding Advisory Support: For their ongoing $30–40 Million Series A financing round. The capital will be utilized to fund Phase 3 clinical trials, manufacturing readiness, and the final New Drug Application (NDA) filing.
"We are highly energized to represent this breakthrough cardiovascular asset," said the leadership at Aagami, Inc. "By transforming a highly effective but complex treatment into a safe, office-prescribed, out-patient option, this technology represents a multi-billion-dollar paradigm shift in atrial fibrillation care. We look forward to connecting the company with elite global partners and investors to accelerate its path to the market."
If you are interested in this, please contact us on action@aagami.com
The client is a specialized cardiovascular pharmaceutical company formed as a strategic joint venture between leading drug development and electrophysiology research organizations. Led by a deeply experienced executive team with over a century of combined expertise in pharmaceutical engineering, clinical operations, and biostatistics, the company is dedicated to developing optimized, patient-centric treatment options for cardiac arrhythmias.
Aagami is a specialized global consulting firm that helps life sciences, biotechnology, and medical device companies achieve global growth. Through strategic partnering, technology licensing, and cross-border joint ventures, Aagami bridges the gap between innovative technologies and high-growth international healthcare markets.